CA2978893A1 - Materiels et methodes pour susciter des reponses anticorps ciblees in vivo - Google Patents

Materiels et methodes pour susciter des reponses anticorps ciblees in vivo

Info

Publication number
CA2978893A1
CA2978893A1 CA2978893A CA2978893A CA2978893A1 CA 2978893 A1 CA2978893 A1 CA 2978893A1 CA 2978893 A CA2978893 A CA 2978893A CA 2978893 A CA2978893 A CA 2978893A CA 2978893 A1 CA2978893 A1 CA 2978893A1
Authority
CA
Canada
Prior art keywords
cell
antibody
cancer
protein
collagen
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
CA2978893A
Other languages
English (en)
Inventor
Stephen J. Weiss
David T. Dudley
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
University of Michigan System
Original Assignee
University of Michigan System
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from US14/642,246 external-priority patent/US20150174224A1/en
Application filed by University of Michigan System filed Critical University of Michigan System
Publication of CA2978893A1 publication Critical patent/CA2978893A1/fr
Abandoned legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/30—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
    • A61K35/13—Tumour cells, irrespective of tissue of origin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/0005—Vertebrate antigens
    • A61K39/0011—Cancer antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/42—Proteins; Polypeptides; Degradation products thereof; Derivatives thereof, e.g. albumin, gelatin or zein
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/80—Vaccine for a specifically defined cancer
    • A61K2039/812—Breast
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2513/00—3D culture
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2533/00—Supports or coatings for cell culture, characterised by material
    • C12N2533/50—Proteins
    • C12N2533/54—Collagen; Gelatin
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2533/00—Supports or coatings for cell culture, characterised by material
    • C12N2533/50—Proteins
    • C12N2533/56—Fibrin; Thrombin
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2537/00—Supports and/or coatings for cell culture characterised by physical or chemical treatment
    • C12N2537/10—Cross-linking

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Immunology (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Cell Biology (AREA)
  • Organic Chemistry (AREA)
  • Biomedical Technology (AREA)
  • Mycology (AREA)
  • Virology (AREA)
  • Engineering & Computer Science (AREA)
  • Microbiology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Oncology (AREA)
  • Biotechnology (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • Zoology (AREA)
  • Developmental Biology & Embryology (AREA)
  • Inorganic Chemistry (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)

Abstract

L'invention concerne des méthodes permettant de générer et identifier des anticorps se liant spécifiquement à des molécules cibles exprimées par des cellules incluses dans une matrice extracellulaire tridimensionnelle ressemblant à l'environnement et la forme de la cible in vivo. L'invention concerne également des méthodes de production d'immunogènes qui produisent des cibles sous de telles formes. L'invention concerne en outre des méthodes permettant d'identifier des agents thérapeutiques anticancéreux, tels que des produits de type anticorps. L'invention concerne également des hydrogels, et ces hydrogels peuvent comprendre une protéine réticulée. L'invention concerne également des agents diagnostiques, des agents prophylactiques et des agents thérapeutiques identifiés à l'aide des méthodes décrites dans la description.
CA2978893A 2015-03-09 2016-03-09 Materiels et methodes pour susciter des reponses anticorps ciblees in vivo Abandoned CA2978893A1 (fr)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US14/642,246 US20150174224A1 (en) 2011-05-19 2015-03-09 Materials and Methods for Eliciting Targeted Antibody Responses In Vivo
US14/642,246 2015-03-09
PCT/US2016/021608 WO2016145112A1 (fr) 2015-03-09 2016-03-09 Matériels et méthodes pour susciter des réponses anticorps ciblées in vivo

Publications (1)

Publication Number Publication Date
CA2978893A1 true CA2978893A1 (fr) 2016-09-15

Family

ID=56879328

Family Applications (1)

Application Number Title Priority Date Filing Date
CA2978893A Abandoned CA2978893A1 (fr) 2015-03-09 2016-03-09 Materiels et methodes pour susciter des reponses anticorps ciblees in vivo

Country Status (4)

Country Link
EP (1) EP3268393A4 (fr)
AU (1) AU2016229060A1 (fr)
CA (1) CA2978893A1 (fr)
WO (1) WO2016145112A1 (fr)

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20070048325A1 (en) * 2005-08-24 2007-03-01 Dennis Van Epps Combination therapies for inhibiting integrin-extracellular matrix interactions
EP2046835B1 (fr) * 2006-08-11 2011-10-26 Schering Corporation Anticorps dirigés contre l'il-17a
US20110052695A1 (en) * 2009-04-20 2011-03-03 Allergan, Inc. Drug delivery platforms comprising silk fibroin hydrogels and uses thereof
WO2010146078A2 (fr) * 2009-06-16 2010-12-23 Bergen Teknologioverføring As Nouvelles utilisations de compositions d'hydroxyproline
AU2012255143A1 (en) * 2011-05-19 2014-02-20 The Regents Of The University Of Michigan Integrin alpha-2 binding agents and use thereof to inhibit cancer cell proliferation

Also Published As

Publication number Publication date
EP3268393A4 (fr) 2018-09-19
EP3268393A1 (fr) 2018-01-17
WO2016145112A1 (fr) 2016-09-15
AU2016229060A1 (en) 2017-09-28

Similar Documents

Publication Publication Date Title
CA3027417C (fr) Anticorps anti-trop-2 humain presentant une activite antitumorale in vivo
CN103073641B (zh) 在体内具有抗肿瘤活性的抗人Dlk-1抗体
TWI402078B (zh) 抗ｃｓｆ－１ｒ抗體
Zanvit et al. Antitumor activity of AZD0754, a dnTGFβRII-armored, STEAP2-targeted CAR-T cell therapy, in prostate cancer
CN101432307B (zh) 显示cd44表面表达的细胞的细胞毒性介导
JP5823858B2 (ja) 抗ｖｅｇｆ抗体
JP6972030B2 (ja) 抗ｎ−アセチルグルコサミン及びｎ−アセチルガラクトサミンの抗体
EP3202788A1 (fr) Anticorps à liaison d'endosialin
TW201542591A (zh) 含有以人源化抗Ｅｐｉｒｅｇｕｌｉｎ抗體爲有效成分的腺癌以外的非小細胞肺癌之治療劑
JP2015514062A (ja) Ｅ−カドヘリンの細胞外ドメインの阻害剤を含む併用療法
KR102516712B1 (ko) 전이성 질환을 치료하기 위한 rankl-특이적 제제
JP2019528437A (ja) 腫瘍関連マクロファージをターゲティングすることによるガン疾患の処置方法
CN117069848A (zh) 抗人cd146兔单克隆抗体及其应用
CA3130113A1 (fr) Anticorps diriges contre un polypeptide apparente a la molecule d'adhesion cellulaire/regule negativement par les oncogenes (cdon) et utilisations associees
US20200254077A1 (en) Materials and Methods for Eliciting Targeted Antibody Responses In Vivo
CA3092434A1 (fr) Compositions d'un nouvel anticorps ceacam6 anti-humain et utilisations connexes
Masuko et al. Towards therapeutic antibodies to membrane oncoproteins by a robust strategy using rats immunized with transfectants expressing target molecules fused to green fluorescent protein
TWI782000B (zh) 抗ｇｐｒ２０抗體、其製造方法及其應用
CA2978893A1 (fr) Materiels et methodes pour susciter des reponses anticorps ciblees in vivo
US20230080534A1 (en) Semg2 antibody and use thereof
CA3025756A1 (fr) Anticorps anti-prl3
EP1819736A2 (fr) Utilisation de proteines de liaison a l'endosialine afin d'isoler des cellules positives pour l'endosialine
US11965028B1 (en) Neuropilin-1-peptide based antibody, highlighting new epitope associated to glycosaminoglycan-modified neuropilin-1 and methods of use thereof
ES2729729T3 (es) Anticuerpos que se unen a PLAC1 y bloquean la interacción entre PLAC1 y FGF7
WO2025184480A2 (fr) Anticorps dirigés contre un polypeptide apparenté à la molécule d'adhésion cellulaire/régulé négativement par les oncogènes (cdon) et utilisations associées

Legal Events

Date Code Title Description
FZDE Discontinued

Effective date: 20210909